Airlock
Smart, secure and compliant data export solution
Company profile
Company profile
Lifebit is a precision medicine and genomics company that has developed the world's leading Federated Trusted Research Environment (TRE) platform. The company's technology enables secure, compliant analysis of health data at unprecedented scale—over 275 million patient records—without requiring data to move from its source. This federated approach solves critical challenges in health AI and research where data cannot be centralized due to privacy, sovereignty, or technical constraints. Lifebit's platform suite includes the Trusted Research Environment for turning data into insights, Trusted Data Lakehouse for connecting and cataloging federated data, Trusted Data Hub for querying distributed data as one, and Airlock for secure data governance and export. The company also offers Lifebit R.E.A.L. for real-time drug side effects and disease outbreak surveillance, and specialized solutions for target identification, clinical interpretation, and biomarker discovery. The platform serves multiple sectors including pharmaceutical companies, health systems, government agencies, nonprofits, and data providers. Lifebit's technology has been peer-reviewed and featured in The Lancet Oncology (2025) for enabling federated breast cancer discovery on Genomics England data. The company's approach enables data harmonization, NGS analysis, and OMOP/FHIR standardization across distributed datasets, with customers reporting that processes that normally take years can be completed in minutes. Lifebit's Trusted Data Marketplace provides access to diverse health datasets spanning cardiometabolic, central nervous system, inflammatory, and oncology conditions, supporting clinical trial optimization, patient registries, and translational research at scale.
Company description Lifebit official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: FHIR, Genomics England, NGS data pipelines, OMOP.
Company milestones
Featured in The Lancet Oncology 2025 for federated breast cancer discovery. NLM Federated Data Workshop participation demonstrating years-to-minutes data harmonization capability.
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Smart, secure and compliant data export solution
Real-time drug side effects and disease outbreak surveillance
Platform for turning data into clinical actions
Automated platform for making data usable
Query federated data as one, instantly
Platform for connecting and cataloging federated data
Access data from 275M+ patients
Federated platform for turning data into insights with secure, in-place analysis
Platform for turning data into drug targets
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Journal of biomedical informatics · Aug 12, 2026
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis.The Lancet. Oncology · Nov 1, 2025
NANOME: A Nextflow pipeline for haplotype-aware allele-specific consensus DNA methylation detection by nanopore long-read sequencing.bioRxiv : the preprint server for biology · Jul 4, 2025
Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.Chemico-biological interactions · Jan 25, 2023
Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis.Phytomedicine : international journal of phytotherapy and phytopharmacology · Jan 1, 2023
MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors.Cell reports · Nov 22, 2022
Clinical validation
No linked records are currently available.
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
breast cancer patients via federated discovery
data stays in place while compute moves to it
federated data connection and harmonization
accessible through federated platform
Federated breast cancer discovery research enabling breakthrough in cancer treatment
27% cure rate improvement for breast cancer patients; study published in The Lancet Oncology 2025
Federated data connection and harmonization across distributed health data sources
Minutes instead of years for data processing and harmonization through centralized, auditable workflow
05 · Leadership
Leadership profiles and professional links from the current Company record.
Dr Daniella Black
Research Lead
Professor Serena Nik-Zainal
Professor, University of Cambridge
06 · Company updates
Recent articles published on Lifebit's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.